An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives-Reference-Cited by-同舟云学术

An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives

Published:2023-01-13 Issue:2 Volume:30 Page:93-107
ISSN:1179-1985
Container-title:High Blood Pressure & Cardiovascular Prevention
language:en
Short-container-title:High Blood Press Cardiovasc Prev

Author:

Sharifi-Rad Javad^ORCID,Sharopov Farukh,Ezzat Shahira M.,Zam Wissam,Ademiluyi Adedayo Oluwaseun,Oyeniran Olubukola Helen,Adetunji Charles Oluwaseun,Roli Osahon Itohan,Živković Jelena,Martorell Miquel,Docea Anca Oana,El Omari Nasreddine,Bouyahya Abdelhakim,Lorenzo José M.,Calina Daniela

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40292-023-00562-9.pdf

Reference142 articles.

1. Puddu PE, Iannetta L, Placanica A, Cuturello D, Schiariti M, Manfrini O. The role of Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and the interference with anemia. Int J Cardiol. 2016;222:1091–6.

2. Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost. 1999;82(2):318–25.

3. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. Lancet. 1996;347(9018):1833.

4. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334(17):1090–4.

5. Walter DH, Schächinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350(9086):1217–9.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention;Journal of Clinical Medicine;2024-07-19

2. Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial;J CARDIOVASC THORAC;2024

3. Outcomes, risk factors, and procedural management of acute myocardial infarction caused by stent thrombosis;Vessel Plus;2024-05-11

4. Recent advances in microfluidic technology of arterial thrombosis investigations;Platelets;2024-02-23

5. Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT);Expert Opinion on Pharmacotherapy;2024-02-11